SEC 13F Intelligence

General Atlantic, L.P. / AKRO

General Atlantic, L.P.’s Akero Therapeutics Inc Com Position

Does General Atlantic, L.P. own Akero Therapeutics Inc Com (AKRO)? Not currently — the last reported position was 5.73M shares worth $272M in Q3 2025; the fund’s latest 13F (Q1 2026) no longer reports it.

Position Value
$272M
Q3 2025
Shares
5.73M
% of Portfolio
+8.17%
Quarters Held
10
position exited

Position History AKRO

Reported value by quarter
Q2 ’23: $83MQ2 ’23Q3 ’23: $90MQ4 ’23: $42MQ4 ’23Q1 ’24: $132MQ2 ’24: $123MQ2 ’24Q3 ’24: $150MQ4 ’24: $146MQ4 ’24Q1 ’25: $212MQ2 ’25: $306MQ2 ’25Q3 ’25: $272Mfilingsflow.com
QuarterSharesValue% of Portfolio
Q3 20255.73M$272M+8.17%
Q2 20255.73M$306M+8.43%
Q1 20255.23M$212M+7.11%
Q4 20245.23M$146M+5.18%
Q3 20245.23M$150M+4.27%
Q2 20245.23M$123M+3.86%
Q1 20245.23M$132M+3.07%
Q4 20231.79M$42M+0.60%
Q3 20231.79M$90M+1.39%
Q2 20231.79M$83M+1.31%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See General Atlantic, L.P.’s full portfolio or all institutional holders of AKRO.